Frontiers in Clinical Drug Research - Alzheimer Disorders: Volume 7

 
 
Frontiers in Clinical Drug Research - Alzheimer Disorders (Verlag)
  • 1. Auflage
  • |
  • erschienen am 2. November 2018
  • |
  • 275 Seiten
 
E-Book | ePUB mit Adobe DRM | Systemvoraussetzungen
978-1-68108-560-9 (ISBN)
 

Frontiers in Clinical Drug Research - Alzheimer Disorders is a book series concerned with Alzheimer's disease AD, a disease that causes dementia, or loss of brain function. This disease affects parts of the brain that affect memory, thought, and languag

  • Englisch
  • Sharjah
  • |
  • Vereinigte Arabische Emirate
PublishDrive
  • 1,32 MB
978-1-68108-560-9 (9781681085609)
weitere Ausgaben werden ermittelt
  • Intro
  • CONTENTS
  • PREFACE
  • List of Contributors
  • Deep Brain Stimulation in the Treatment of Alzheimer's disease
  • Angelo Lavano*, Giusy Guzzi, Attilio Della Torre, Domenico Chirchiglia, Carmelino Angelo Stroscio, Donatella Gabriele and Giorgio Volpentesta
  • INTRODUCTION
  • DBS TARGETS USED IN PATIENTS WITH AD
  • Fornix
  • Nucleus Basalis of Meynert
  • Entorhinal Cortex/Hippocampus
  • Pedunculopontine Tegmental Nucleus
  • Anterior Thalamic Nucleus
  • Anterior Limb of Internal Capsule/Nucleus Accumbens
  • DISCUSSION
  • CONCLUSION
  • CONSENT FOR PUBLICATION
  • CONFLICT OF INTEREST
  • ACKNOWLEDGEMENTS
  • REFERENCES
  • ASS234: A New and Promising Anti-Alzheimer Agent
  • Alejandro Romero1,*, Eva Ramos1, Ana P. Fernández2, Julia Serrano2, Ricardo Martínez-Murillo2 and José Marco-Contelles3
  • INTRODUCTION
  • Design and Synthesis of ASS234 Strategy
  • Biological and Pharmacological Evaluation of ASS234
  • Signal Transduction Pathways Involved in ASS234-Induced Neuroprotection
  • The Proof of Concept of ASS234
  • CONCLUDING REMARKS
  • CONSENT FOR PUBLICATION
  • CONFLICT OF INTEREST
  • ACKNOWLEDGEMENTS
  • REFERENCES
  • Recent Advances in Alzheimer's Drug Discovery Research
  • Xin-An Liu1,6,*, Brati Das2, Youjun Chen3, Zuxin Chen4, Yosef Avchalumov1, Xu Tian5 and Sathyanarayanan V. Puthanveettil1,*
  • INTRODUCTION
  • The Prevalence of Alzheimer's Disease from Epidemiological Studies and Public Health Impact
  • GENETIC DETERMINANTS OF ALZHEIMER'S DISEASE
  • Molecular Genetic Phenotypes of Alzheimer's Disease
  • The Role of ncRNAs in AD
  • BEHAVIORAL AND ELECTROPHYSIOLOGICAL STUDIES IN TRANSGENIC MODELS OF ALZHEIMER'S DISEASE
  • CELLULAR AND PHYSIOLOGICAL MECHANISMS OF ALZHEIMER'S DISEASE AND PHARMACOTHERAPEUTIC TARGETS
  • Amyloid-ß Aggregation
  • Tauopathies and Neurofibrillary Tangles (NFTs)
  • Molecular Pathways of Neurodegeneration in Alzheimer's Disease
  • Roles of Glycogen Synthase Kinase 3 (GSK-3) in AD
  • Roles of Cyclin-Dependent Kinase 5-p25
  • Roles of MAPK and ERK Kinases
  • Roles of Fyn Kinase
  • Roles of p21-Activated Kinase
  • Roles of JNK Kinases
  • Inflammation and Immune Response
  • Apoptosis and Aberrant Cell Cycle Regulation
  • Recent Drug Development in Alzheimer's Disease
  • Acetylcholinesterase (AChE) Inhibitors to Treat Dementia Associated with Alzheimer's Disease
  • Inhibition of Amyloid-ß Aggregation
  • Advances in Tau-based Drug Discovery
  • Emerging Cognitive Enhancing Drugs
  • Glutamate Excitotoxicity and New Anti-Excitotoxicity Strategies in Alzheimer's Disease
  • Epigenetic Therapeutics for AD
  • FUTURE DIRECTIONS AND NEW TRENDS IN THE DESIGN OF DRUGS AGAINST ALZHEIMER'S DISEASE
  • CONSENT FOR PUBLICATION
  • CONFLICT OF INTEREST
  • ACKNOWLEDGEMENTS
  • REFERENCES
  • Alzheimer's Disease and Proteasome: The Therapeutic Development and Management
  • Qunxing Ding* and Haiyan Zhu
  • INTRODUCTION
  • GENETICS AND STRUCTURE OF PROTEASOME
  • ASSOCIATION BETWEEN PROTEASOME AND LYSOSOME
  • ASSOCIATION BETWEEN PROTEASOME AND RIBOSOME
  • IMPAIRMENT OF PROTEASOME IN AGING AND AD
  • UBIQUITINATION, SUMOYLATION AND NEDDYLATION IN AD
  • IMMUNOPROTEASOME IN AGING AND AD
  • THERAPEUTIC STUDY RELATED TO PROTEASOME
  • SOME CLINICAL TRAILS FOR AD
  • Clinical Trials for Verubecestat (MK-8931)
  • Clinical Trials for Pinitol (NIC5-15)
  • Clinical Trials for EVP-0962
  • Clinical Trials for EGCG (Epigallocatechin-Gallate)
  • Clinical Trials for Tramiprosate (3APS)
  • Clinical Trials for Bexarotene
  • Clinical Trials for Estrogen
  • Clinical Trials for Azeliragon
  • Clinical Trials for Valproic Acid
  • Clinical Trials for Bapineuzumab
  • Clinical Trials for Lithium
  • Clinical Trial for Methylene Blue
  • Clinical Trial for Rilapladib
  • AD MANAGEMENT: DIET
  • AD MANAGEMENT: SLEEPING
  • AD MANAGEMENT: LIFESTYLE
  • AD MANAGEMENT: GENDER
  • AD MANAGEMENT: ASSOCIATION WITH OTHER DISEASES
  • FUTURE DIRECTIONS
  • CONSENT FOR PUBLICATION
  • CONFLICT OF INTEREST
  • ACKNOWLEDGEMENTS
  • REFERENCES
  • Alzheimer´s Disease: Fundamental Concepts, Novel Findings and Therapeutics Outcomes Coming from the Ca2+/cAMP Signalling Interaction
  • Leandro Bueno Bergantin*
  • INTRODUCTION
  • PATHOPHYSIOLOGICAL ROLE OF THE NEURONAL CA2+ HOMEOSTASIS IN AD
  • NEURONAL CA2+ SIGNALLING AS A POTENTIAL TARGET FOR THE PHARMACOTHERAPY OF AD
  • PHARMACOLOGICAL MODULATION OF THE CA2+/CAMP SIGNALLING AS A POTENTIAL NEUROPROTECTIVE STRATEGY FOR THE AD THERAPY
  • CONCLUSIONS
  • SUMMARY POINTS
  • ABBREVIATIONS
  • CONSENT FOR PUBLICATION
  • CONFLICT OF INTEREST
  • ACKNOWLEDGEMENTS
  • REFERENCES
  • Alzheimer's Disease: An Approach for Non-Pharmacological Therapies
  • M.G.V. Gottlieb1,*, V.E. Closs2, V.M. Junges3, A. von Gunten4, Z.C.L. Lindôso5, J.P. Rocha1, B.J.P. Lopes Filho1, C.R. Oliveira6 and F. Loureiro1
  • INTRODUCTION
  • ALZHEIMER'S DISEASE AND THE CONVENTIONAL PHARMACOLOGICAL THERAPY
  • Alzheimer's Disease
  • NEUROPSYCHOLOGIST ASSESSMENT AND INTERVENTION
  • Cognition and AD
  • Neuropsychological Assessment in Alzheimer's Disease
  • Strategies of Cognitive Stimulation
  • OCCUPATIONAL THERAPY ASSESSMENT AND INTERVENTION
  • PHYSICAL EDUCATOR ASSESSMENT AND INTERVENTION
  • Physical Exercise and Cognition in AD
  • Intervention Strategies for Patients with AD
  • PHYSIOTHERAPIST ASSESSMENT AND INTERVENTION
  • NUTRITIONAL ASSESSMENT AND INTERVENTION
  • Food as a Protective Factor Against AD
  • Nutritional Strategy in Modulating AD Mechanisms and Vulnerabilities
  • Nutritional Management - Actions, Therapies and Interventions - to Postpone the Functional and Nutritional Decline of the Elderly with AD
  • Initial or Mild Disease Phase
  • Weight Loss in AD
  • Nutritional Management
  • Moderate Disease Phase
  • Nutritional Management
  • Severe Disease Phase
  • Nutritional Management
  • SPEECH ASSESSMENT AND INTERVENTION
  • Dysphagia
  • Clinical Signs
  • Management
  • Modification in Consistency and Volume of Food
  • Direct Approaches to the Patient
  • Alternative Feeding Route
  • CONCLUDING REMARKS
  • ABBREVIATIONS
  • CONSENT FOR PUBLICATION
  • CONFLIT OF INTEREST
  • ACKNOWLEDGEMENTS
  • REFERENCES
  • Past and Present Drug Development for Alzheimer's Disease
  • Pratap Kumar Sahu*, Prashant Tiwari, Shakti Ketan Prusty and Bharat Bhusan Subudhi
  • INTRODUCTION
  • THERAPEUTIC MANAGEMENT
  • DRUG DISCOVERY PROGRAMME
  • NMDA Receptor Antagonists
  • Cholinergic Drugs
  • Amyloid-Targeted Therapies
  • Decreasing Aß Production
  • Promoting Aß Clearance
  • Preventing Aß Aggregation
  • Drugs Targeting Tau protein
  • Neurotrophins
  • Drugs Targeting Mitochondrial Dysfunction
  • REPURPOSING OF DRUGS
  • Drugs Acting on COX Pathway
  • Drugs Acting on LOX Pathway
  • Drugs Acting on Renin Angiotensin System
  • Lipid Lowering Drugs
  • Anti-Diabetics
  • Antioxidants
  • Vitamin D
  • Dextromethorphan
  • Vitamin B-12
  • MAPK Inhibitor
  • Serotonergic Drugs
  • Cannabinoids
  • Glycine Transporter Inhibitor
  • Melatonin
  • Tetracyclines
  • Lithium
  • Valproic Acid
  • Methylene Blue
  • Nicotine
  • CONCLUSION
  • CONSENT FOR PUBLICATION
  • CONFLICT OF INTEREST
  • ACKNOWLEDGEMENTS
  • REFERENCES
  • SUBJECT INDEX

Dateiformat: EPUB
Kopierschutz: Adobe-DRM (Digital Rights Management)

Systemvoraussetzungen:

Computer (Windows; MacOS X; Linux): Installieren Sie bereits vor dem Download die kostenlose Software Adobe Digital Editions (siehe E-Book Hilfe).

Tablet/Smartphone (Android; iOS): Installieren Sie bereits vor dem Download die kostenlose App Adobe Digital Editions (siehe E-Book Hilfe).

E-Book-Reader: Bookeen, Kobo, Pocketbook, Sony, Tolino u.v.a.m. (nicht Kindle)

Das Dateiformat EPUB ist sehr gut für Romane und Sachbücher geeignet - also für "fließenden" Text ohne komplexes Layout. Bei E-Readern oder Smartphones passt sich der Zeilen- und Seitenumbruch automatisch den kleinen Displays an. Mit Adobe-DRM wird hier ein "harter" Kopierschutz verwendet. Wenn die notwendigen Voraussetzungen nicht vorliegen, können Sie das E-Book leider nicht öffnen. Daher müssen Sie bereits vor dem Download Ihre Lese-Hardware vorbereiten.

Bitte beachten Sie bei der Verwendung der Lese-Software Adobe Digital Editions: wir empfehlen Ihnen unbedingt nach Installation der Lese-Software diese mit Ihrer persönlichen Adobe-ID zu autorisieren!

Weitere Informationen finden Sie in unserer E-Book Hilfe.


Download (sofort verfügbar)

116,40 €
inkl. 5% MwSt.
Download / Einzel-Lizenz
ePUB mit Adobe DRM
siehe Systemvoraussetzungen
E-Book bestellen